1. Christopherson WM, Foote Jr FW, Stewart FW: Alveolar soft‐part sarcomas. Structurally characteristic tumors of uncertain histogenesis. Cancer 1952, 5(1):100-111.
2. Portera Jr CA, Ho V, Patel SR, Hunt KK, Feig BW, Respondek PM, Yasko AW, Benjamin RS, Pollock RE, Pisters PW: Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer 2001, 91(3):585-591.
3. Wang H, Jacobson A, Harmon DC, Choy E, Hornicek FJ, Raskin KA, Chebib IA, DeLaney TF, Chen YL: Prognostic factors in alveolar soft part sarcoma: A SEER analysis. Journal of surgical oncology 2016, 113(5):581-586.
4. Lieberman PH, Brennan MF, Kimmel M, Erlandson RA, Garin‐Chesa P, Flehinger BY: Alveolar soft‐part sarcoma. A clinico‐pathologic study of half a century. Cancer 1989, 63(1):1-13.
5. Ogose A, Yazawa Y, Ueda T, Hotta T, Kawashima H, Hatano H, Morita T, Japanese Musculoskeletal Oncology G: Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. Oncology 2003, 65(1):7-13.
6. WHO_Classification_of_Tumours_Editorial_Board: WHO classification of tumours of soft tissue and bone, 5th edition. International agency for research on cancer, Lyon 2020.
7. Font RL, Jurco III S, Zimmerman LE: Alveolar soft-part sarcoma of the orbit: a clinicopathologic analysis of seventeen cases and a review of the literature. Human pathology 1982, 13(6):569-579.
8. Pappo AS, Parham DM, Cain A, Luo X, Bowman LC, Furman WL, Rao BN, Pratt CB: Alveolar soft part sarcoma in children and adolescents: clinical features and outcome of 11 patients. Medical and Pediatric Oncology: The Official Journal of SIOP—International Society of Pediatric Oncology (Societé Internationale d'Oncologie Pédiatrique 1996, 26(2):81-84.
9. Casanova M, Ferrari A, Bisogno G, Cecchetto G, Basso E, De Bernardi B, Indolfi P, Bellani FF, Carli M: Alveolar soft part sarcoma in children and adolescents: A report from the Soft-Tissue Sarcoma Italian Cooperative Group. Annals of Oncology 2000, 11(11):1445-1449.
10. FUREY JG, BARRETT DL, SEIBERT RH: Alveolar soft-part sarcoma: report of a case presenting as a sacral bone tumor. JBJS 1969, 51(1):185-190.
11. O'Toole RV, Tuttle SE, Lucas JG, Sharma HM: Alveolar soft part sarcoma of the vagina: an immunohistochemical and electron microscopic study. International journal of gynecological pathology: official journal of the International Society of Gynecological Pathologists 1985, 4(3):258-265.
12. Nolan N, Gaffney E: Alveolar soft part sarcoma of the uterus. Histopathology 1990, 16(1):97-99.
13. Yagihashi S, Yagihashi N, Hase Y, Nagai K, Alguacil-Garcia A: Primary alveolar soft-part sarcoma of stomach. The American journal of surgical pathology 1991, 15(4):399-406.
14. Durkin RC, Johnston JO: Alveolar soft part sarcoma involving the ilium: a case report. Clinical Orthopaedics and Related Research® 1999, 359:197-202.
15. Fletcher M: Primary alveolar soft part sarcoma of bone. Histopathology 1999, 35(5):411-417.
16. Ogura K, Beppu Y, Chuman H, Yoshida A, Yamamoto N, Sumi M, Kawano H, Kawai A: Alveolar soft part sarcoma: a single-center 26-patient case series and review of the literature. Sarcoma 2012, 2012:907179.
17. Hagerty BL, Aversa J, Diggs LP, Dominguez DA, Ayabe RI, Blakely AM, Davis JL, Luu C, Hernandez JM: Characterization of alveolar soft part sarcoma using a large national database. Surgery 2020, 168(5):825-830.
18. Paoluzzi L, Maki RG: Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review. JAMA Oncol 2019, 5(2):254-260.
19. Penel N, Robin Y-M, Blay J-Y: Personalised management of alveolar soft part sarcoma: a promising phase 2 study. The Lancet Oncology 2019, 20(6):750-752.
20. Lazar AJ, Das P, Tuvin D, Korchin B, Zhu Q, Jin Z, Warneke CL, Zhang PS, Hernandez V, Lopez-Terrada D: Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clinical Cancer Research 2007, 13(24):7314-7321.
21. Penel N, Coindre JM, Giraud A, Terrier P, Ranchere-Vince D, Collin F, Guellec SLE, Bazille C, Lae M, de Pinieux G et al: Presentation and outcome of frequent and rare sarcoma histologic subtypes: A study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers. Cancer 2018, 124(6):1179-1187.
22. Nakano K, Takahashi S: Current molecular targeted therapies for bone and soft tissue sarcomas. International journal of molecular sciences 2018, 19(3):739.
23. van der Graaf WT, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet 2012, 379(9829):1879-1886.
24. Kawai A, Yonemori K, Takahashi S, Araki N, Ueda T: Systemic therapy for soft tissue sarcoma: proposals for the optimal use of pazopanib, trabectedin, and eribulin. Advances in therapy 2017, 34(7):1556-1571.
25. Ayodele O, Razak A: Immunotherapy in soft-tissue sarcoma. Current Oncology 2020, 27(s1):17-23.
26. Martín-Broto J, Moura DS, Van Tine BA: Facts and hopes in immunotherapy of soft-tissue sarcomas. Clinical Cancer Research 2020, 26(22):5801-5808.
27. Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, Wieder ED, Kolonias D, Rosenberg AE, Kerr DA et al: Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. The Lancet Oncology 2019, 20(6):837-848.
28. Amin MB, Edge SB: AJCC cancer staging manual: springer; 2017.
29. Enneking WF, Spanier SS, Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clinical orthopaedics and related research 1980, 153:106-120.
30. Flores RJ, Harrison DJ, Federman NC, Furman WL, Huh WW, Broaddus EG, Okcu MF, Venkatramani R: Alveolar soft part sarcoma in children and young adults: A report of 69 cases. Pediatric blood & cancer 2018, 65(5):e26953.
31. Folpe A, Deyrup A: Alveolar soft-part sarcoma: a review and update. Journal of clinical pathology 2006, 59(11):1127-1132.
32. Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, Stacchiotti S, Casali PG, Gronchi A: Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. Annals of surgical oncology 2010, 17(12):3229-3233.
33. Reichardt P, Lindner T, Pink D, Thuss-Patience P, Kretzschmar A, Dörken B: Chemotherapy in alveolar soft part sarcomas: what do we know? European Journal of Cancer 2003, 39(11):1511-1516.
34. Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I: UK guidelines for the management of soft tissue sarcomas. Clinical sarcoma research 2016, 6:20.
35. Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee J, Brodowicz T et al: Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2018, 29(Suppl 4):iv51-iv67.
36. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM et al: Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018, 16(5):536-563.
37. Kim M, Kim TM, Keam B, Kim YJ, Paeng JC, Moon KC, Kim DW, Heo DS: A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. Oncologist 2019, 24(1):20-e29.
38. Liu J, Fan Z, Li S, Gao T, Xue R, Bai C, Zhang L, Tan Z, Fang Z: Target therapy for metastatic alveolar soft part sarcoma: a retrospective study with 47 cases. Ann Transl Med 2020, 8(22):1493.
39. Oh CR, Hong JY, Kim JH, Lee JS, Kim HS, Kim TW, Ahn JH, Kim JE: Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study. Target Oncol 2020, 15(4):485-493.
40. Shido Y, Matsuyama Y: Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years. Case Rep Oncol Med 2017, 2017:3738562.
41. Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY: Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma. The oncologist 2018, 23(1):62.
42. Jagodzinska-Mucha P, Switaj T, Kozak K, Kosela-Paterczyk H, Klimczak A, Lugowska I, Rogala P, Wagrodzki M, Falkowski S, Rutkowski P: Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma. Tumori 2017, 103(3):231-235.
43. Urakawa H, Kawai A, Goto T, Hiraga H, Ozaki T, Tsuchiya H, Nakayama R, Naka N, Matsumoto Y, Kobayashi E et al: Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study. Cancer Sci 2020, 111(9):3303-3312.
44. Liu J, Fan Z, Bai C, Li S, Xue R, Gao T, Zhang L, Tan Z, Fang Z: Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma. Ann Transl Med 2021, 9(4):339.
45. Mariuk-Jarema A, Kosela-Paterczyk H, Rogala P, Klimczak A, Wagrodzki M, Maksymiuk B, Rutkowski P: A durable complete response to immunotherapy in a patient with metastatic alveolar soft part sarcoma. Tumori 2020, 106(6):NP9-NP13.
46. Ogose A, Morita T, Hotta T, Kobayashi H, Otsuka H, Hirata Y, Yoshida S: Brain metastases in musculoskeletal sarcomas. Japanese journal of clinical oncology 1999, 29(5):245-247.
47. Malouf GG, Beinse G, Adam J, Mir O, Chamseddine AN, Terrier P, Honore C, Spano JP, Italiano A, Kurtz JE et al: Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group. The Oncologist 2019, 24(7):980-988.